Veracyte reports 11% metastasis reduction in prostate trial

• Veracyte reported a retrospective analysis of 401 patients from the Phase III STAMPEDE trial, examining whether Decipher Prostate scores predict benefit from adding abiraterone to androgen deprivation therapy.
• At five years, absolute reductions in distant metastasis events were 10% for patients with high Decipher scores, 11% for those with very high scores and 2% for those with lower scores.
• Veracyte plans to present the findings at the ESMO 2026 Congress on October 24, alongside broader research supporting Decipher's role in prostate cancer risk assessment.

Veracyte (NASDAQ:VCYT) reported an analysis of Phase III STAMPEDE trial data suggesting its Decipher Prostate test may help identify patients who benefit from adding abiraterone to treatment.

The retrospective analysis included 401 patients with very high-risk nonmetastatic prostate cancer receiving androgen deprivation therapy alone or with abiraterone.

“The Decipher Prostate study will provide the first evidence that the test predicts benefit from adding abiraterone to treatment for patients with clinically very high-risk disease,” said Veracyte Chief Scientific and Medical Officer Phillip Febbo.

At five years, abiraterone was associated with absolute reductions in distant metastasis events of 10% for high Decipher scores, 11% for very high scores and 2% for lower scores.

The treatment-by-Decipher interaction was statistically significant among node-negative patients (p=0.01), indicating that the relationship between treatment benefit and genomic score varied across groups.

A separate real-world analysis involving more than 27,000 patients supported Decipher's prognostic value, while higher genomic scores in STAMPEDE were associated with worse survival outcomes.

Veracyte will present the findings at ESMO on October 24, 2026, expanding its research into using genomic testing to inform prostate cancer treatment decisions.